About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Your One-Stop Clinical Data Superstore? | Main | Dumpster Diving for Data? »

June 11, 2004

The Agents Report Back

Email This Entry

Posted by Derek

Now that ASCO's wrapped up (and the American Diabetes Association meeting as well) every attendee from the drug industry has gone back to report on the news: copies of poster presentations, handwritten notes from the talks, and (most importantly) information that was only given verbally. That would be in answers to questions after a talk, in conversation around a poster, or in small gatherings all over the place.

That sort of stuff is often the real gold from a large meeting. No one is going to spill anything vital, but you can often learn more than is strictly contained in the official presentations, and everything helps. The drug industry being what it is, we have plenty of things we'd like to know about what the competition is up to: Are they still interested in compound X? Have they moved on to another one? What's better about it? Is that side effect something that's showing up in the whole class of compounds? How did they ever dose that stuff at those levels, anyway? Are they in Phase II? In what sort of patients?

It's a well-known psychological effect in the business that we treat new information as something that's just happened. But you have to keep in mind that the information in these meeting presentations is at best several months old, and maybe older than that. (At least it's better than getting excited about a paper that's just shown up in the literature.) That's another reason for all the one-on-one questioning, naturally - we want to know, for once, what's happening right now.

Comments (1) + TrackBacks (0) | Category: The Scientific Literature


1. The Un-Candidate on June 13, 2004 6:30 PM writes...

Are there any famous examples of "security breaches" from these meetings, where someone really let the cat out of the bag?

I've always wondered if pharmaceutical companies perform "active intelligence" (sifting through their garbage, etc.) against their competitors as opposed to "passive intelligence" (patents, papers, etc.)

Permalink to Comment


Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry